Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

287 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
[Development and validation of novel clinical endpoints in intermediate age-related macular degeneration in MACUSTAR].
Terheyden JH, Finger RP, Schmitz-Valckenberg S, Agostini H, Dahlke C, Kuehlewein L, Lang GE, Pauleikhoff D, Wolf A, Boettger MK, Luhmann UFO, Asmus F, Holz FG; MACUSTAR-Konsortium. Terheyden JH, et al. Among authors: agostini h. Ophthalmologe. 2019 Dec;116(12):1186-1193. doi: 10.1007/s00347-019-0907-1. Ophthalmologe. 2019. PMID: 31087116 Review. German.
Repeatability and Discriminatory Power of Chart-Based Visual Function Tests in Individuals With Age-Related Macular Degeneration: A MACUSTAR Study Report.
Dunbar HMP, Behning C, Abdirahman A, Higgins BE, Binns AM, Terheyden JH, Zakaria N, Poor S, Finger RP, Leal S, Holz FG, Schmid M, Crabb DP, Rubin GS, Luhmann UFO; MACUSTAR Consortium. Dunbar HMP, et al. JAMA Ophthalmol. 2022 Aug 1;140(8):780-789. doi: 10.1001/jamaophthalmol.2022.2113. JAMA Ophthalmol. 2022. PMID: 35737401 Free PMC article.
[Central serous chorioretinopathy].
Pauleikhoff L, Agostini H, Lange C. Pauleikhoff L, et al. Among authors: agostini h. Ophthalmologe. 2021 Sep;118(9):967-980. doi: 10.1007/s00347-021-01376-7. Epub 2021 Apr 16. Ophthalmologe. 2021. PMID: 33861376 Review. German.
Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials.
Heier JS, Khanani AM, Quezada Ruiz C, Basu K, Ferrone PJ, Brittain C, Figueroa MS, Lin H, Holz FG, Patel V, Lai TYY, Silverman D, Regillo C, Swaminathan B, Viola F, Cheung CMG, Wong TY; TENAYA and LUCERNE Investigators. Heier JS, et al. Lancet. 2022 Feb 19;399(10326):729-740. doi: 10.1016/S0140-6736(22)00010-1. Epub 2022 Jan 24. Lancet. 2022. PMID: 35085502 Clinical Trial.
Intravitreal 5-Fluorouracil and Heparin to Prevent Proliferative Vitreoretinopathy: Results from a Randomized Clinical Trial.
Schaub F, Schiller P, Hoerster R, Kraus D, Holz FG, Guthoff R, Agostini H, Spitzer MS, Wiedemann P, Lommatzsch A, Boden KT, Dimopoulos S, Bemme S, Tamm S, Maier M, Roider J, Enders P, Altay L, Fauser S, Kirchhof B; PRIVENT Study Group. Schaub F, et al. Among authors: agostini h. Ophthalmology. 2022 Oct;129(10):1129-1141. doi: 10.1016/j.ophtha.2022.05.024. Epub 2022 Jun 7. Ophthalmology. 2022. PMID: 35680097 Clinical Trial.
287 results